Fresenius Accelerates Momentum in its (Bio)Pharma Business and Launches Tyenne®*, its Third Approved Biosimilar in the U.S.
Tyenne® is the first tocilizumab biosimilar by Fresenius Kabi, an operating company of Fresenius, with an intravenous an…
Tyenne® is the first tocilizumab biosimilar by Fresenius Kabi, an operating company of Fresenius, with an intravenous an…
Three performance levels for injection vials, syringes, ampoules and cartridges Clear and consistent structure for s…
Organic revenue growth in 2023: +10.4% Organic adjusted EBITDA growth in 2023: +17.5% Favorable product mix boosts p…
The term “biotherapies” broadly refers to medicinal products, including biopharmaceuticals, that are produced from biolo…
Broad portfolio for biologics, including cell and gene therapy products Digitally connected Drug Delivery Devices for s…
Subcutaneous administration of oncology drugs with digital therapy support Integrating Gx SensAir drug delivery device w…
Messenger RNA (mRNA) nanomedicines, a ground-breaking technology that has led to the development of the first approved C…
Significant expansion of production capacities for RTF syringes for the North American market Investment volume of aroun…
. - Shatter-resistant injection vials maximize patient and production safety - Optional Velocity coating for outstanding…
Gerresheimer presents an extensive portfolio of containment solutions, drug delivery systems and digital therapy suppor…